H.C. Wainwright downgrades RAPT shares to neutral after clinical trial halt By Investing.com
[ad_1] © Reuters. On Wednesday, RAPT Therapeutics (NASDAQ:) faced a downgrade from H.C. Wainwright, moving from Buy to Neutral, following a pause in all clinical...